Midday Market Movements: Oracle Declines, IDEXX Soars, Rivian Upgraded
- Oracle’s stock fell 6% after announcing plans for a $20 billion financing to support AI initiatives.
- IDEXX Laboratories shares surged 20% following better-than-expected earnings and revenue.
- Rivian’s stock increased 10% after UBS upgraded the electric vehicle maker’s rating to buy.
Several companies experienced significant stock movements during midday trading. Oracle’s stock dropped 6% after the company filed plans on Monday to issue new stock and increase its debt by $10 billion each in common stock and senior notes, aimed at financing its artificial intelligence development. This filing was submitted to the Securities and Exchange Commission.
IDEXX Laboratories experienced a remarkable 20% rise in its stock price after reporting third-quarter results that surpassed earnings and revenue estimates. The veterinary diagnostics firm’s revenue reached $1.21 billion, marking a 10% increase year-over-year. Furthermore, IDEXX raised its revenue and earnings forecasts for 2026, although it lowered expectations for operating margin.
Tempus AI saw its stock climb nearly 12%, buoyed by third-quarter earnings that beat Wall Street estimates. The precision-medicine company reported revenue of $411.5 million, a 23% increase from the previous year, with its data and applications segment growing by 33% and oncology volume increasing by 32%. The company also revised its revenue forecast for 2026 upward while maintaining its adjusted EBITDA outlook.
SpaceX shares rose over 3% after reports emerged from The Washington Post that the rocket and satellite company is negotiating to acquire Dish Network’s Boost Mobile subsidiary or explore utilizing its network. Such a move could position CEO Elon Musk within the $235 billion wireless market.
Rivian’s stock surged 10% after UBS analysts upgraded the electric vehicle manufacturer to a ‘buy’ rating. Analyst Joseph Spak highlighted Rivian’s recent decline in stock price as presenting a buying opportunity ahead of anticipated growth in sales of the R2 midsize SUV.
Conversely, memory stocks such as Micron, SanDisk, and Western Digital fell between 3% and 5%, continuing a downward trend from Friday. Marvell Technology shares decreased by 9% while Lumentum’s stock plummeted 15% after Marvell announced an all-stock acquisition of the maker of high-performance lasers in a deal valued at $115 billion. This transaction is expected to conclude in the first half of 2028.
Energy stocks, including ExxonMobil, Chevron, and Valero, also faced declines, with shares retracing 3% to 5% as oil prices dropped at the start of the week. Meanwhile, Krystal Biotech’s stock plunged nearly 15% after the company disclosed delays in the release of data for several treatments, including KB801, a gene therapy for neurotrophic keratitis, expected to be postponed to 2027. This announcement overshadowed a strong third-quarter performance relative to consensus estimates.
News Courtesy of CNBC
